Literature DB >> 7045695

Redistribution of intermediate filaments during capping of lymphocyte surface molecules.

K Dellagi, J C Brouet.   

Abstract

Intermediate filaments (IF) constitute a major cytoplasmic filamentous network of higher eukaryotic cells that is distinct from actin and myosin microfilaments or microtubules. Although structurally similar, these filaments are formed by chemically and antigenically different proteins. Vimentin is the major IF polypeptide of mesenchymal cells and cultured non-mesenchymal cell lines. Recently, we have characterized a monoclonal IgM antibody from a patient with Waldenström's macroglobulinaemia which is directed against vimentin. Using this monoclonal antibody, we have shown by direct immunofluorescence that intermediate filaments of human B and T lymphocytes consist of vimentin. In cells exposed to colcemid, the intermediate filaments retracted into a juxtanuclear aggregate ('coli') characteristic of vimentin filaments. As most components of the cytoskeleton, especially actin and myosin, have been implicated in the capping phenomenon, we investigated the effect of capping of either beta 2-microglobulin or membrane immunoglobulins on the organization of the intermediate filament network. We report that capping of these surface molecules induced the redistribution of vimentin just beneath the cap. When colcemid-treated cells were allowed to cap, the location of the cap always coincided with the coil, suggesting that the anchorage point of intermediate filaments is situated within the uropod.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7045695     DOI: 10.1038/298284a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  11 in total

1.  Complex and dynamic redistribution of NF-kappaB signaling intermediates in response to T cell receptor stimulation.

Authors:  Brian C Schaefer; John W Kappler; Abraham Kupfer; Philippa Marrack
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-14       Impact factor: 11.205

2.  Cytoskeletal polarity in mammalian lymphocytes in situ.

Authors:  J K Lee; E A Repasky
Journal:  Cell Tissue Res       Date:  1987-01       Impact factor: 5.249

3.  Functional changes of intermediate filaments in fibroblastic cells revealed by a monoclonal antibody.

Authors:  R Dulbecco; R Allen; S Okada; M Bowman
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

4.  Redistribution of fodrin (a component of the cortical cytoplasm) accompanying capping of cell surface molecules.

Authors:  J Levine; M Willard
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

5.  Epstein-Barr virus latent infection membrane protein increases vimentin expression in human B-cell lines.

Authors:  M Birkenbach; D Liebowitz; F Wang; J Sample; E Kieff
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

6.  Vimentin filaments in spreading, randomly locomoting, and f-met-leu-phe-treated neutrophils.

Authors:  L M Parysek; B S Eckert
Journal:  Cell Tissue Res       Date:  1984       Impact factor: 5.249

7.  Alteration of vimentin intermediate filament expression during differentiation of human hemopoietic cells.

Authors:  K Dellagi; W Vainchenker; G Vinci; D Paulin; J C Brouet
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

8.  Tenascin-C and alpha-smooth muscle actin positive cells are increased in the large airways in patients with COPD.

Authors:  Magnus Löfdahl; Riitta Kaarteenaho; Elisa Lappi-Blanco; Göran Tornling; Magnus C Sköld
Journal:  Respir Res       Date:  2011-04-15

9.  Calcium-dependent association of a protein complex with the lymphocyte plasma membrane: probable identity with calmodulin-calcineurin.

Authors:  P D Chantler
Journal:  J Cell Biol       Date:  1985-07       Impact factor: 10.539

10.  Establishment of a functional human immunodeficiency virus type 1 (HIV-1) reverse transcription complex involves the cytoskeleton.

Authors:  A Bukrinskaya; B Brichacek; A Mann; M Stevenson
Journal:  J Exp Med       Date:  1998-12-07       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.